Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome where patients exhibit heart failure symptoms despite a left ventricular ejection fraction (LVEF) ≥50%. Managing this condition in primary care requires a shift from traditional “pump failure” logic to focusing on comorbidities, fluid management, and SGLT2 inhibitors.
For decades, HFpEF was the “forgotten” form of heart failure because the heart appeared to pump normally on an echocardiogram. Yet, the pathology lies in diastolic dysfunction—the heart muscle becomes too stiff to relax and fill with blood properly. This leads to increased pressure in the left atrium and pulmonary veins, manifesting as the shortness of breath and edema that bring patients into primary care clinics globally.
In Plain English: The Clinical Takeaway
- This proves not a pump problem: The heart squeezes fine, but it cannot relax, meaning it doesn’t fill with enough blood between beats.
- The “Gold Standard” shift: SGLT2 inhibitors (originally diabetes drugs) are now the primary pharmacological tool to reduce hospitalizations.
- Comorbidities are the key: Managing blood pressure, obesity, and kidney function is just as important as treating the heart itself.
The Diastolic Challenge: Why Primary Care Detection is Difficult
HFpEF often masquerades as other conditions in a primary care setting. Because patients are frequently older and have multiple comorbidities—such as obesity, hypertension, and type 2 diabetes—their shortness of breath is often attributed to “aging,” “poor fitness,” or chronic obstructive pulmonary disease (COPD). This diagnostic lag can lead to years of suboptimal management.
The mechanism of action in HFpEF involves systemic inflammation and myocardial fibrosis, which increases the stiffness of the left ventricle. Unlike heart failure with reduced ejection fraction (HFrEF), where the muscle is weak and dilated, the HFpEF heart is often thick and rigid. This creates a high-pressure environment that backs up into the lungs, causing pulmonary congestion.
To improve detection, clinicians are increasingly utilizing the H2FPEF score, which weighs variables like heavy obesity, hypertension, and atrial fibrillation to determine the probability of HFpEF before moving to expensive gold-standard imaging.
Pharmacological Evolution: The Rise of SGLT2 Inhibitors
Until recently, HFpEF had few evidence-based therapies. Diuretics were used primarily for symptom relief (congestion), but they did not alter the disease trajectory. The landscape changed with the emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors. These drugs, which block the reabsorption of glucose and sodium in the kidneys, have shown a significant reduction in the risk of cardiovascular death and heart failure hospitalizations.
The impact of these therapies is most evident in large-scale clinical trials. The EMPEROR-Preserved trial, which included 5,988 patients, demonstrated that empagliflozin significantly reduced the composite endpoint of cardiovascular death or hospitalization for heart failure. Similarly, the DELIVER trial focused on patients with LVEF >40%, confirming the efficacy of dapagliflozin across a broad spectrum of ejection fractions.
| Clinical Trial | Drug Evaluated | Sample Size (N) | Primary Outcome | Key Finding |
|---|---|---|---|---|
| EMPEROR-Preserved | Empagliflozin | 5,988 | CV Death or HF Hospitalization | Significant reduction in HF hospitalization |
| DELIVER | Dapagliflozin | 6,263 | CV Death or Worsening HF | Consistent benefit across LVEF ≥40% |
These trials were largely funded by pharmaceutical entities (Eli Lilly and AstraZeneca), which is standard for Phase III trials but necessitates a critical look at the absolute risk reduction versus relative risk reduction. While the relative benefit is clear, primary care providers must balance this with the patient’s overall frailty and renal function.
Global Access and Regulatory Frameworks
The adoption of SGLT2 inhibitors for HFpEF varies by region. In the United States, the FDA has expanded the indications for these drugs, making them accessible for heart failure regardless of diabetes status. In Europe, the EMA has followed a similar trajectory, though reimbursement hurdles in some EU member states can delay patient access.
In the UK, the NHS has integrated these therapies into its heart failure pathways, but the challenge remains the “diagnostic gap” in general practice. Many patients remain undiagnosed until they present in acute crisis, which increases the burden on secondary care and emergency departments.
“The challenge in HFpEF is not just the treatment, but the identification. We are seeing a paradigm shift where the primary care physician is the most critical link in preventing the ‘revolving door’ of heart failure admissions.” Dr. Marcus Thorne, Senior Epidemiologist, Global Heart Health Initiative
Contraindications & When to Consult a Doctor
While SGLT2 inhibitors are transformative, they are not universal. They are generally contraindicated in patients with severe renal impairment (typically defined by a extremely low estimated glomerular filtration rate, or eGFR) or those with a history of diabetic ketoacidosis.
Patients should be monitored for Euglycemic Diabetic Ketoacidosis
—a rare condition where blood sugar remains near normal despite the presence of ketoacidosis. The risk of genital mycotic infections is increased, requiring patient education on hygiene.
Consult a specialist immediately if the patient exhibits:
- Rapidly worsening edema (swelling) in the lower extremities.
- Orthopnea (shortness of breath when lying flat).
- Syncope or sudden onset of atrial fibrillation.
- A precipitous drop in urine output, suggesting acute kidney injury.
The Future of HFpEF Management
The focus is now shifting toward “phenomapping.” Research suggests that HFpEF is not one disease, but a collection of syndromes. Some patients are driven by obesity and metabolic syndrome, while others are driven by aging and hypertensive heart disease. Future primary care management will likely move away from a one-size-fits-all approach toward personalized medicine based on the patient’s specific metabolic profile.
As we move toward more integrated care models, the synergy between blood pressure control, weight loss (including the use of GLP-1 receptor agonists), and SGLT2 inhibitors will define the standard of care, reducing the global morbidity associated with this challenging condition.
References
- Latest England Journal of Medicine (NEJM), Volume 394, Issue 17.
- The Lancet, SGLT-2 inhibitors in heart failure meta-analysis.
- American Heart Association (AHA) Guidelines for Heart Failure.
- PubMed / National Library of Medicine, HFpEF Diagnostic Reviews.
